Up to 60% of patients with multiple sclerosis (MS) experience cognitive dysfunction, with prominent involvement of complex attention, information processing speed, executive functions, episodic memory, and visuospatial abilities. Since MS-related cognitive deficits can substantially affect a wide range of daily life activities (e.g., work, driving, social integration, and adherence to medication regimens), it is imperative that we identify and develop strategies to alleviate them.
Let's rehabilitate cognitive rehabilitation in multiple sclerosis Up to 60% of patients with multiple sclerosis (MS) experience cognitive dysfunction, with prominent involvement of complex attention, information processing speed, executive functions, episodic memory, and visuospatial abilities. Since MS-related cognitive deficits can substantially affect a wide range of daily life activities (e.g., work, driving, social integration, and adherence to medication regimens), it is imperative that we identify and develop strategies to alleviate them.
Whether cognitive rehabilitation is effective in patients with MS is still a matter of debate. Two recent Cochrane reviews 1, 2 concluded that there is a low level of evidence for a positive effect of cognitive rehabilitation programs for persons with MS. However, the types of intervention that were considered were heterogeneous, and the conclusions were limited by the suboptimal quality of many of the primary studies; methodologic limitations included small patient samples, lack or inadequacy of control groups, incompleteness of the neuropsychological assessment, absence of standardized training tools, and lack of appropriate outcome measures. Therefore, randomized controlled trials (RCTs) conducted with better methodology are clearly needed to ascertain the utility of cognitive rehabilitation in MS. If effective, such treatment will dramatically improve patients' quality of life and optimize medical care and costs.
Computer-assisted cognitive rehabilitation of patients with MS has the potential to improve attention, executive functions, and memory performances. 3, 4 These studies have also shown that the beneficial effect of cognitive rehabilitation is not limited to the trained domain but also extends to fatigue, depression, and quality of life, 4 even several months after treatment termination. 5 Compensatory strategies, which may have been optimized during the training period, might contribute to and explain these ancillary and prolonged effects. Indeed, functional MRI (fMRI) investigations 6,7 detected brain functional modifications, likely induced by training, which may reflect the neurobiological substrates of the observed posttreatment improvement.
The article by Chiaravalloti et al. 8 published in this issue of Neurology ® elegantly illustrates how a rigorous study design can contribute to the advancement of our understanding of the role of cognitive rehabilitation in patients with MS. This double-blind placebo-controlled RCT assessed the efficacy of the modified Story Memory Technique to improve learning and memory performance in MS patients with new learning impairment. Patients were randomly assigned to treatment (n 5 41) or placebo (n 5 45). At baseline, none of the variables analyzed differed between the 2 groups. Following the completion of the treatment phase, which lasted 5 weeks, patients in the treatment arm were assigned to a monthly booster-session or a non-booster-session group to assess whether this integrated strategy was able to facilitate the maintenance of the treatment effect over the following 6 months.
Immediately following completion of the first part of the study, the treatment group showed improvements in learning slope, everyday memory tests, and self-reported general contentment as well as decreases in informant-reported apathy and executive dysfunction in daily life compared to the placebo group. These data confirm and extend earlier findings, suggesting that cognitive rehabilitation exerts a positive effect that is not limited to the trained function but extends to several additional domains, thus ultimately improving patients' quality of life.
The second important result of this RCT comes from the analysis of the extension phase of the study. Unfortunately, this included a smaller sample of patients (n 5 38 for treatment, n 5 35 for placebo). Nevertheless, those in the treatment arm continued to experience posttreatment improvement on the listlearning and self-report measures. Administering booster sessions during this 6-month period did not provide additional benefits. This is the first study providing Class I evidence supporting the efficacy of cognitive rehabilitation in patients with MS. One of its most intriguing results is the confirmation that a wide-range enhancement of functional abilities is achieved with rehabilitation of specific cognitive domains. This calls for the identification of the underlying substrates, which may involve recovery of functionally damaged brain regions, use-dependent plasticity, development of additional or "latent" pathways, or a combination of these and other mechanisms. fMRI has the potential to shed light on this, but, unfortunately, no such data are reported in this manuscript (although MRI data from a small subset have been published elsewhere). 9 Clearly, there are several issues that remain unexplored, which have important implications not only for practicing physicians and therapists but also for future research in the field. Such issues include, for example, identification of who would benefit the most, "dosage" and duration parameters, timing of when interventions should commence and for how long, and the delineation of practice effects related to the longitudinal administration of neuropsychological tests. From this perspective, a concerning collateral finding of Chiaravalloti et al. 8 is the worsening in everyday memory in the placebo group at the end of the 5-week treatment. Outside of an acute relapse, cognitive deterioration in MS is known to occur at a relatively slow pace. Therefore, whether this finding is an unexpected effect of the type of training administered to the placebo group or, conversely, reflects a limited ability to capture relevant modifications of cognition induced by the disease over a relatively short period with "standard" neuropsychological assessment needs to be established. Another important point that requires future investigation is the role of brain and cognitive reserve on outcomes of cognitive rehabilitation in MS. 10 Indeed, patients with a low cognitive reserve are at higher risk for cognitive decline, particularly in memory functions, whereas high cognitive reserve protects against cognitive deterioration. 10 Would this help to select patients who may benefit most from early cognitive rehabilitation? Additional methodologically sound RCTs, like this one, are needed to advance cognitive rehabilitation in MS. This well-designed investigation provides the clinician with the knowledge that behavioral interventions for cognitive dysfunction in MS are currently available and should be utilized.
